Blog

MindMed to Participate in the Canaccord Genuity 42nd Annual Growth Conference

Aug 4 • 1 min read

Mind Medicine Inc. (NASDAQ: MNMD | NEO: MMED), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that members of MindMed’s management team will participate in the Canaccord Genuity 42nd Annual Growth Conference, to be held in Boston, MA, August 8-11, 2022. Canaccord Genuity 42nd Annual Growth ConferenceFormat: In-person…

Retreats and the Transformative Effects of Ketamine

Aug 4 • 3 min read

Presented by What would it look like to create a profound, lasting transformation in your life? To completely rewire your brain to support growth and flexibility? To open yourself up to new awareness and insights you have never considered? To spark creativity and inspiration you have never imagined? Or to address and heal trauma from…

PSYC Corp’s Psychedelic Spotlight Surpasses One Million Page Views for Third Consecutive Month

Aug 3 • 5 min read

PSYC Corporation (OTCPink: PSYC), a media leader focused on the emerging psychedelic sector, announced that its flagship platform, Psychedelic Spotlight, surpassed one million Page Views in the month of July, as well as setting new monthly records for the following KPI’s: Page Views, Impressions, Organic Visits, and Click Thru Rate (CTR). The accomplishment comes after…

Algernon Pharmaceuticals Invited to Present Phase 2 IPF and Chronic Cough Study Data at 9th American Cough Conference

Aug 3 • 2 min read

Algernon Pharmaceuticals Inc. (CSE: AGN | FRANKFURT: AGW0 | OTCQB: AGNPF) a clinical stage Canadian pharmaceutical development company, is pleased to announce it has been invited to present the results from its Phase 2a Study of NP-120 (“Ifenprodil”) for idiopathic pulmonary fibrosis and Chronic Cough, at the 9th American Cough Conference in June, 2023. The American…

Canadian Patent Grant Strengthens Small Pharma’s International Position

Aug 3 • 2 min read

Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, today announces that as of July 19, 2022 it has been granted patent no. 3104072 by the Canadian Intellectual Property Office. This Canadian patent protects Composition of Matter of certain deuterated analogues of N, N-dimethyltryptamine, including…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441442443444445446447448449450451452453454455456457458459460461462463464465466467468469470471472473474475476477478479480481482483484485486487488489490491492493494495496497498499500501502503504505506507508509510511512513514515516517518519520521522523524525526527528529530531532533534535536537538